• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Orchestra BioMed wins CE Mark for BackBeat hypertension neurostim, names CMO

Orchestra BioMed wins CE Mark for BackBeat hypertension neurostim, names CMO

September 5, 2019 By Sean Whooley

Orchestra BioMed said yesterday that it received the CE Mark for its Moderato implantable pulse generator system for BackBeat cardiac neuromodulation therapy (CNT), just nine days after naming a new chief medical officer.

BackBeat therapy is a bioelectronic treatment designed to lower blood pressure while modulating the autonomic nervous system. The Moderato implantable device is designed to deliver BackBeat CNT and provide standard pacemaker functions.

In July, New Hope, Penn.-based Orchestra BioMed announced it had closed a $34 million Series B preferred stock funding round and said it could receive up to an additional $57 million in follow-on investments. At the time, the company said the proceeds would be used to accelerate and expand the development of its lead assets, namely BackBeat CNT.

Dr. Karl-Heinz Kuck, director of cardiology at the Lans Medicum, Hamburg, Germany, and principal investigator for the Moderato’s clinical trials, will present the latest study of BackBeat CNT, titled Moderato II, on Sept. 28 at the Transcatheter Cardiovascular Therapeutics 2019 conference in San Francisco.

“BackBeat CNT is an exciting new approach to device-based blood pressure management and has potential to be a primary treatment modality for the more than two-thirds of pacemaker patients at risk from hypertension,” Kuck said in a news release. “In the Moderato I clinical trial, BackBeat CNT demonstrated excellent efficacy and safety results, particularly given that 78% of the study patients had isolated systolic hypertension and that patients’ average baseline ambulatory systolic blood pressure (137 mmHg) was lower compared to patients in other device-based hypertension studies. I look forward to presenting the six-month primary endpoint results from the Moderato II study of BackBeat CNT as a late-breaker at TCT later this month.”

“CE Mark approval and selection for late-breaking science presentation at TCT validate the potential for BackBeat CNT to benefit targeted high-risk hypertensive patients, such as those already indicated for a pacemaker,” added Orchestra BioMed CEO David Hochman. “Effective treatment of these patients, the majority of whom have isolated systolic disease and persistent high blood pressure despite conventional pharmaceutical therapies, represents a significant market opportunity that could have substantial growth, value and market share implications for the field of cardiac rhythm management.”

The CE Mark approval came days after the company’s announcement that Dr. Dennis Donohoe would take over as chief medical officer.

Donohoe was worldwide vice president of clinical, regulatory and medical affairs for Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corporation a for 11 years. He has owned Donohoe Clinical Consultants for the past four years, previously serving as a part-time chief medical officer for Orchestra BioMed’s Focal Therapies group and its predecessor, Caliber Therapeutics, as a consultant.

“Dennis Donohoe is a proven leader with extensive clinical and regulatory experience directly relevant to our therapeutic device product pipeline. We are thrilled that Dennis has agreed to join our management team on a full-time basis,” Hochman said in a news release. “We could not ask for a more qualified leader as we prepare to initiate a global clinical and regulatory development program focused on multiple coronary and peripheral indications for Virtue (sirolimus-eluting balloon) in collaboration with Terumo, our strategic partner. His extensive knowledge and expertise will also be vital to further our clinical and regulatory plans for BackBeat CNT for hypertension, our other flagship product, as well as additional pipeline development initiatives we expect to embark on in the future.”

“I am excited to assume a full-time role as part of Orchestra BioMed’s leadership team during this critical growth period when I can help advance the development of Virtue SEB for coronary and peripheral artery disease as well as BackBeat CNT for targeted high blood pressure patient populations,” added Donohoe. “As a physician, I was impressed by how these therapies have the potential to improve outcomes in areas of high unmet medical need while seamlessly integrating into existing clinical workflows within interventional cardiology and cardiac rhythm management. I truly believe that eventual regulatory approval and adoption of these technologies could have a lasting impact for patients, physicians and hospital systems worldwide.”

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Featured, Neuromodulation/Neurostimulation, News Well, Regulatory/Compliance Tagged With: Orchestra BioMed, Personnel Moves

In case you missed it

  • The top 7 medtech CEO quotes on COVID-19, one year later
  • Forest Devices touts study of stroke detection tech
  • Thermo Fisher completes Mesa Biotech acquisition
  • ICU Medical dips despite Street-beating Q4
  • Silk Road Medical touts results of large TCAR study
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
  • 8 drug delivery innovations you need to know
  • Terumo to acquire Health Outcomes Sciences
  • iRhythm’s revenue jumps 33% in Q4
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • NuVasive reports mixed Q4 results
  • Is J&J’s COVID-19 vaccine linked to tinnitus?
  • UK passes post-Brexit medical device regulation
  • Stereotaxis up on Street-beating Q4 results
  • Nevro posts Street-beating Q4 results
  • Kala Pharmaceuticals slides on missed Q4 projections
  • FDA approves EndoClot hemostat for GI bleeding

RSS From Medical Design & Outsourcing

  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]
  • Interpower debuts plugs in new colors
    Interpower announced that its NEMA 5-20 hospital-grade plugs for use in North America now come in molded colors of clear, black or gray on 10-foot lengths of flexible cord. These molded plugs complement the company’s NEMA 5-20 hand-wired hospital-grade plugs. The North American 18A hospital-grade power cord on 14 AWG SJT cable and North American… […]
  • Portescap motors gain certification
    Portescap announced that its slotless brushless DC motors for respirators have received ISO 13485:2016 certification. Expanding on ISO 9001, this standard contains specific requirements for parts traceability and risk management activities throughout the design and development stages. It also requires process and software validations at defined intervals. Independent risk management and quality compliance firm DNV… […]
  • Instron launches update to product testing system
    Materials testing equipment and software developer Instron announced the launch of the Torsion Add-On 3.0 for universal testing systems. Recently redesigned to take advantage of the latest functionality offered by the new Instron 6800 series, this system offers a simpler, safer, and more intuitive user experience, according to Norwood, Mass.-based Instron. Instron introduced the Torsion… […]
  • Abiomed CEO Michael Minogue appointed as AdvaMed chairperson
    Medtech trade group AdvaMed today said it has appointed Abiomed (NSDQ:ABMD) president and CEO Michael Minogue as chairperson of the AdvaMed board of directors, effective immediately. Minogue will serve as chairperson of the trade association’s board of directors for two years. He has been a member of the board since 2007 and a member of the board… […]
  • Credit card-sized pump could enable ‘power clothing’ to help patients with mobility
    Robotic clothing that is entirely soft and could help people to move more easily is a step closer to reality thanks to the development of a new flexible and lightweight power system for soft robotics. The discovery by a team at the University of Bristol (UK) could pave the way for wearable assist devices for… […]
  • ACSYS Lasertechnik debuts quick-change laser system
    ACSYS Lasertechnik (Lenexa, Kan.) recently announced the development of its patent-pending, ultra-short pulse,  quick-change laser system for marking, engraving and cutting for medical device applications. The system uses a galvanometer scanner equipped with either f-theta marking optics or a laser cutting head to provide interchangeable flexibility and precision. When in marking mode, the system can… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS